Susan Charman

Susan Charman

Professor Susan Charman

Centre from Drug Candidate Optimisation
Monash Institute of Pharmaceutical Sciences
Professor of Pharmaceutics
Director, Centre for Drug Candidate Optimisation

Email: susan.charman@monash.edu
Phone: +61 3 9903 9626
ROPES

A career in pharmaceutical sciences provides me with the opportunity to work at the interface of basic drug discovery and translational research. Working within multidisciplinary drug discovery teams offers a stimulating work environment where chemical, biological and pharmaceutical sciences all need    to    work in unison to identify new drug candidates.


Professor Charman's group is focused on characterising properties associated with absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics (PK) for new drug candidates. Identifying PK liabilities and integrating this information into drug discovery programs is essential to guide  structural  modifications, establish pharmacokinetic/pharmacodynamic (PK/PD) relationships and identify strategies to mitigate risks during drug development. The goal is to play significant role in translating chemical and biological discoveries into viable drug candidates that are well-positioned for  further  development. They have established a successful model for conducting collaborative, multidisciplinary translational research within an academic environment, and have put in place the required systems, processes, platforms, and skill-set to support end-user focused research.

Selected recent publications

Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz  MB,  Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Sci. Transl. Med. 2013;5:177ra137.

Keenan M, Chaplin JH, Alexander PW, Abbott MJ, Best WM, Khong A, Botero A, Perez C, Cornwall S, Thompson RA, White KL, Shackleford DM, Koltun M, Chiu FCK, Morizzi J, Ryan E, Campbell M, von Geldern TW, Scandale I, Chatelain E, Charman SA. Two Analogues of Fenarimol Show Curative Activity in an Experimental  Model  of Chagas Disease. J Med Chem. 2013;56:10158-10170.

Moehrle JJ, Arbe-Barnes S, Siethoff C, van Giersbergen PLM, Craft JC, Duparc S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. First-In-Man Safety and Pharmacokinetics of OZ439, a New Synthetic Ozonide Antimalarial with an Improved Exposure Profile Relative to Available Peroxide Antimalarials.  Br  J Clin Pharmacol. 2013;75:524-537.

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ. Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacol. Rev. 2013;65:315-499.

Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. Malarial Dihydrofolate Reductase as a Paradigm  for  Drug Development against a Resistance-Compromised Target. Proc. Natl. Acad. Sci. U. S. A. 2012;109:16823-16828.

Younis Y, Douelle F, Feng T, González Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 3,5-Diaryl-2-Aminopyridines as  a  Novel Class of Orally Active Antimalarials Demonstrating Single Dose Cure in Mice and Clinical Candidate Potential. J Med Chem. 2012;55:3479-3487.

Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom  JL.  Synthetic Ozonide Drug Candidate Oz439 Offers New Hope for a Single-Dose Cure of Uncomplicated Malaria. Proc. Natl. Acad. Sci. U. S. A. 2011;108:4400-4405.

Coteron JM, Marco M, Esquivias J, Deng X, White KL, White J, Koltun M, El Mazouni F, Kokkonda S, Katneni K, Bhamidipati R, Shackleford DM, Angulo-Barturen I, Ferrer SB, Jimenez-Diaz MB, Gamo FJ, Goldsmith EJ, Charman WN, Bathurst I, Floyd D, Matthews D, Burrows JN, Rathod PK, Charman SA, Phillips MA.  Structure-Guided  Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential. J. Med. Chem. 2011;54:5540-5561.

Creek DJ, Charman WN, Chiu FC, Prankerd RJ, Dong Y, Vennerstrom JL, Charman SA. Relationship between Antimalarial Activity and Heme Alkylation for Spiro- and Dispiro-1,2,4-Trioxolane Antimalarials. Antimicrob. Agents Chemother. 2008;52:1291-12.

Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN. Identification of an Antimalarial Synthetic Trioxolane Drug Development Candidate.  Nature.  2004;430:900-904.